Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by JLGeminion Feb 25, 2011 12:30pm

256 Views

Post# 18194521

RE: Way to go ...

Reads like a sales pitch to me. I wish them luck. I prefer announcements by the US NCI researches announcing trial results. They tend to be independent and unbiased. There are rumours that some biotechs and pharma pump trial results and hide negative information. I'm sure that I can take your endorsement of this company as gospel haititrader. Your reputation preceeds you. LOL

Bullboard Posts

Canadian psychedelic stock to supply MDMA to Yale